2013


To access this material please log in or register

Register Authorize
2013/№2

NEbivolol vs. MEtoprolol: comparative randomized Study In patientS with Chronic Heart Failure (NEMESIS-CHF)

Mareev V. Yu., Danielyan M. O., Osmolovskaya Yu. F., Ageev F. T., Seredenina E. M., Zhubrina E. S., Lopatin Yu. M., Platonova Yu. V., Ivanenko V. V., Privalova E. V., Zheleznykh E. A.

Keywords: treatment, metoprolol, nebivolol, CHF

DOI: 10.18087 / rhfj.2013.2.1815

Background. The β-adrenoblocker (β-AB) therapy is an essential part of therapy for HF. The choice of β-AB is based on results of clinical studies and includes the drugs which have been proven prognostically beneficial for patients with CHF. Aim. Comparing efficacy and safety of nebovilol and metoprolol tartrate therapy in patients with CHF. Materials and methods. The study included 107 patients with II–III NYHA FC CHF. 58 (54.2 %) of these patients received nebivolol and 49 (45.8 %) patients received metoprolol tartrate. The treatment duration was 24 weeks. During the treatment period, patients received a standard therapy for CHF. Patients were evaluated for changes in their clinical condition by CCS, CHF FC, control of heart rate and BP, ECG, echoCG, arterial wall stiffness, central pressure, 6min walk test, plasma level of brain natriuretic peptide (BNP), blood biochemistry, insulin resistance (IR) degree using HOMA-IR, and biochemical markers of collagen metabolism. Results. Nebivolol was not inferior to metoprolol by the heart rate and BP control in patients with CHF and reduced LV EF. Nebivolol improved the systolic and diastolic heart function to the same degree as metoprolol and was superior to metoprolol in reducing myocardial hypertrophy and left ventricle unloading. Additional vasodilatory effects of nebovilol, as distinct from classic β-AB, allow reducing the intra-aortic resistance to heart ejection in patients with CHF. Nebovilol has an advantage over metoprolol in controlling glucose metabolism, reducing IR, and controlling collagen metabolism. The additional (to selective β-blockade) properties of nebivolol determine its higher clinical efficacy (time course of CHF FC, CSS score, and 6min walk distance) compared to the traditional β-AB metoprolol.
  1. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  2. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119 (14):1977–2016.
  3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  4. CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS–II): a randomized trial. Lancet. 1999;353 (9146):9–13.
  5. Flather MD, Shibata MC, Coats AJS, and the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215–225.
  6. Fowler MB. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. Am J Cardiol. 2004;93 (9A): 35B-39B.
  7. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
  8. Packer M, Bristow MR, Cohn JN et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334 (21):1349–1355.
  9. Cooke JP. The endotelium: a new target for therapy. Vasc Med. 2000;5 (1):49–53.
  10. Haffner SM, Kennedy E, Gonzalez C et al. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care. 1996;19 (10):1138–1141.
  11. Matthews DR, Hosker JP, Rudenski AS et al. Homeostatis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28 (7):412–419.
  12. Redon J. Cardio-metabolic effects of antihypertensive treatment. 5th International Meeting on Nitric Oxide «Nitric Oxide and its role in cardiovascular diseases». – Paris, 4–5 May, 2007. – P. 34–36.
  13. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail. 2005;7 (4):631–639.
  14. Евдокимова А. Г., Радзевич А. Э., Терещенко О. И и др. Небиволол в лечении ишемической болезни сердца с хронической сердечной недостаточностью. Кардиология. 2004;47 (2):15–18.
  15. Ghio S, Magrini G, Serio A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006; 27 (5):562–568.
  16. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104 (5):511–514.
  17. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004;44 (3):305–310.
  18. Zanchetti A. Clinical pharmacodymamics of nebivolol: new evidence of nitric oxidemediated vasodilatating activity and peculiar hemodynamic properties in hypertensive patients. Blood Pressure. 2004;13 (Suppl 1):17–32.
  19. Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the mana­gement of hypertension and chronic heart failure. Drugs. 2006;66 (10):1389–409.
  20. Kuroedov A, Cosentino F, Luscher TF. Pharmacologic mechanisms of clinically favorable properties of a selective b1‑adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev. 2004;22 (3):155–168.
  21. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999 Apr;57 (4):633–51.
  22. Moen MD, Wagstaff AJ. Nebivolol: A review of its use in the mana­gement of hypertension and chronic heart failure. Drugs. 2006;66 (10):1389–1409.
  23. Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1‑blocker. J Clin Pharmacol. 2008;48 (2):225–239.
  24. Cominacini L, Fratta Pasini A, Garbin U et al. Nebivolol and its 4‑keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42 (10):1838–1844.
  25. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine / NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274 (3):1067–1071.
  26. Williams B, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54 (8):705–713.
  27. Осмоловская Ю. Ф., Мареев В. Ю., Глечян А. М. и др. Арте­ри­аль­ная жесткость и показатели эндотелиальной дисфункции микроциркуляторного русла у пациентов ХСН с сохранной и сниженной сократительной функцией миокарда левого желудочка. Журнал Сердечная Недостаточность. 2011;12 (3):142–148.
  28. Налетов С. В., Валитова И. А. Фармакотерапевтический вектор обеспечения баланса нейрогормональных систем при хронической сердечной недостаточности. Международный Меди­цин­ский Журнал. 2002;8 (4):18–20.
  29. Anker SD, Rauchhaus M. Heart failure as a metabolic problem. Eur J Heart Fail. 1999;1 (2):127–131.
  30. Berard E. Metabolism and regulation of nitric oxide: a hard-to-control mediator. Arch Pediatr. 1997;4 (10):1004–1011.
  31. Амосова Е. Н. Сердечная недостаточность: от новых аспектов патогенеза к совершенствованию диагностики и новым целям лечения. Лiкування та дiагностика. 2000;2:7–12.
  32. Визир А. Д., Дунаев В. В., Березин А. Е., Крайдашенко О. В. Метаболический комплекс в лечении больных пожилого возраста с ишемической болезнью сердца и сердечной недостаточностью. Укр. кард. Журн. 1995;4:34–36.
  33. Никулина Т. Д., Войтович Н,С., Кармазiна О. М. Метформiн i профiлактика серцево-судинних захворювань при метаболiчному синдромi. Укр. мед. Часопис. 2000;2:65–70.
  34. Давыдов А. Л. Влияние метформина и манинила на показатели липидного обмена у больных схарным диабетом типа 2. Пробл. Эндокринологии. 2000;46 (3):10–13.
  35. Лапина Ю. В., Нарусов О. Ю., Мареев В. Ю. и др. Рациональная Эффективная Многокомпонентная терапия в БОрьбе с Сахар­ным Диабетом у больных ХСН (РЭМБО–СД ХСН) Хроническая сердечная недостаточность как фактор риска развития инсулинорезистентности и нарушений углеводного обмена. Журнал Сердечная недостаточность. 2007;8 (4):164–170.
  36. Лапина Ю. В., Петрухина А. А., Нарусов О. Ю. и др. Эффек­тивность и безопасность применения бета-блокатора бисопролола в комплексном лечении больных с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Результаты исследования РЭМБО–СД ХСН. Кардиоваскулярная терапия и профилактика. 2008;1 (4):45–53.
  37. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24 (3):591–596.
  38. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized controlled trial. Ann Intern Med. 1997;126 (12):955–959.
  39. Naruse M, Tanabe A, Takagi S et al. Insulin resistance and vascular function. Nihon Rinsho. 2000;58 (2): – 344–347.
  40. Bakris GL, Fonseca V, Katholi RE et al. for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292 (18):2227–2236.
  41. Fogari R, Zoppi A, Lazzari P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11 (11):753–757.
  42. Jacob S, Rett K, Wicklmayr M et al. Differential effect of chro­nic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14 (4):489–494.
  43. Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19 (8):1429–1435.
  44. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67 (8):1097–1107.
  45. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006;21 (1):20–23.
  46. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15 (4):264–272.
  47. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79 (1):215–262.
  48. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. ardiovasc Res. 1999;41 (3):532–543.
  49. Klappacher G, Franzen P, Haab D et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ische­mic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75 (14):913–918.
  50. Avendano GF, Agarwal RK, Bashey RI et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999;48 (7):1443–1447.
  51. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96 (8):2488–2492.
  52. Kamp O, Sieswarda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92 (3):344–348.
  53. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5 (5):621–627.
  54. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowe­ring effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27 (12):841–849.
  55. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2000;36 (5 Suppl 1):S401–403.
Mareev V. Yu., Danielyan M. O., Osmolovskaya Yu. F. et al. NEbivolol vs. MEtoprolol: comparative randomized Study In patientS with Chronic Heart Failure (NEMESIS-CHF). Russian Heart Failure Journal. 2013;14 (2):63-74

To access this material please log in or register

Register Authorize
Ru En